Introduction

Venous thromboembolism (VTE)—encompassing deep vein thrombosis (DVT) and pulmonary embolism (PE)—remains a significant cause of morbidity and mortality in orthopedic and trauma populations. Among high-risk subgroups, patients with lower limb trauma immobilized in casts face an notably elevated VTE risk due to prolonged immobility, vascular injury, and hypercoagulability associated with tissue trauma. Yet, indiscriminate pharmacologic prophylaxis carries bleeding risks and is resource-intensive. To address this clinical dilemma, the Thrombosis Risk Prediction score following Cast Immobilization (TRiP(cast)) was developed—a validated, point-of-care tool to stratify VTE risk in this specific patient population.

Background and Development

The TRiP(cast) score was derived from a prospective, multicenter cohort study published in Thrombosis and Haemostasis (2017) by Prandoni et al., involving over 2,600 adults with lower limb trauma treated with below-knee or above-knee cast immobilization. The cohort was followed for 3 months for objectively confirmed symptomatic VTE. Multivariable logistic regression identified independent predictors of VTE, which were then assigned weighted points to generate a simple risk score.

Key features of the TRiP(cast) score include:

• Objective validation in external cohorts
• Focus on clinical applicability: all variables are readily available at bedside or in primary care
• Risk stratification into low-, moderate-, and high-risk categories with distinct VTE incidence rates

The TRiP(cast) Score Components

The score incorporates five predictors, each assigned 1 point:

Note: A history of VTE includes prior DVT/PE, and known thrombophilia includes Factor V Leiden, prothrombin G20210A mutation, antithrombin deficiency, etc.

Total Score Range: 0 to 5

Risk Stratification and Predicted VTE Incidence

The TRiP(cast) score categorizes patients into three risk groups with markedly different VTE risks over 3 months:

*Based on derivation cohort; validated in independent cohorts with consistent calibration.

Importantly, the negative predictive value (NPV) in the low-risk group is >99%, supporting safe omission of prophylaxis in this subgroup.

Clinical Utility and Guidelines

The TRiP(cast) score has been incorporated into several clinical guidelines:

• European Society of Cardiology (ESC) Guidelines on Acute VTE (2019): Recommends risk assessment using validated tools like TRiP(cast) in cast-immobilized patients to guide prophylaxis decisions.
• American College of Chest Physicians (ACCP) Guidelines (CHEST 2021): Suggests using clinical prediction rules to identify low-risk patients who may forgo pharmacologic prophylaxis.

Practical Application Example:
A 45-year-old patient with isolated distal tibia fracture treated with a below-knee cast for 3 weeks, BMI 26, no prior VTE or thrombophilia.
TRiP(cast) points: Immobilization ≥2 weeks (1 point).
Total = 1 → Low risk → No routine anticoagulation recommended (unless other comorbidities justify it).

Strengths and Limitations

Strengths:
✅ Simple, fast, and cost-effective
✅ Validated in diverse populations across Europe and North America
✅ High NPV supports safe de-escalation of care
✅ Encourages individualized risk-benefit discussions

Limitations:
❌ Does not incorporate newer biomarkers (e.g., D-dimer) or genetic profiles
❌ Limited data on patients with comorbid malignancy, inflammatory disorders, or recent surgery
❌ Underestimates risk in extremely obese (BMI > 40) or critically ill patients
❌ Not validated for use beyond 3 months follow-up or in non-cast immobilization (e.g., braces, splints)

Integrating TRiP(cast) into Clinical Workflow

To implement the score effectively:

1. Assess at cast application—document all five variables before initiating immobilization
2. Counsel patients on VTE symptoms and red flags regardless of risk category
3. For high-risk (≥3 points): Consider mechanical prophylaxis (e.g., compression stockings) ± pharmacologic prophylaxis for 14–28 days, per institutional protocol and bleeding risk
4. For moderate/low-risk: Emphasize early mobilization, hydration, and patient education; avoid routine anticoagulation
5. Use digital tools or EHR alerts to automate scoring where possible

Future Directions

Ongoing research explores:

• Integration of D-dimer into TRiP(cast) (TRiP(cast)+D-dimer model) for refined risk stratification
• Smartphone-based apps for real-time scoring and reminder systems
• Expansion to non-trauma immobilized populations (e.g., post-op knee arthroscopy)

Conclusion

The TRiP(cast) score represents a major advance in personalized VTE prevention for patients with lower limb trauma. By identifying low-risk individuals who can safely avoid anticoagulation—and high-risk patients who benefit most from intervention—it optimizes clinical outcomes, reduces unnecessary bleeding complications, and supports value-based care. When applied judiciously alongside clinical judgment, the TRiP(cast) score empowers clinicians to make evidence-based decisions at the point of care.

References

1. Prandoni P, et al. Development and validation of a prediction rule for risk of venous thromboembolism in patients with lower limb trauma cast-immobilized: The TRiP(cast) score. Thromb Haemost. 2017;117(5):846–853.
2. Kakkos SK, et al. Validation of the TRiP(cast) risk assessment model in a North American cohort. J Thromb Haemost. 2020;18(Suppl 1):ab218.
3. Anderson DR, et al. Venous thromboembolism prophylaxis and treatment in patients with lower extremity trauma: CHEST guideline and expert panel report. Chest. 2021;159(3):1146–1171.

Disclaimer: The TRiP(cast) score is a clinical decision-support tool and should not replace professional medical judgment. Always assess individual patient factors before initiating or withholding prophylaxis.